Ports of Antwerp and Zeebrugge to Merge

The Belgian cities of Antwerp and Bruges have agreed to merge their respective ports, with the former taking an 80.2% share in the combined port and Bruges taking 19.8%. The merger remains subject to a number of conditions, including approval from Belgian competition authorities.

The unified ports of Antwerp and Zeebrugge – to be known as the Port of Antwerp-Bruges – will remain Europe’s most important chemicals hub and account for more than 15% of European transshipments of liquid natural gas, the port authorities said. In 2019, the Port of Antwerp handled 69 million t of bulk liquids, while Zeebrugge handled 12.6 million t. 

The agreement marks the start of a unification process that is expected to take a year to finalize. Negotiations began in December 2019, following a study the year before to determine the economic complementary strengths from a merger.

Antwerp specializes in chemical products, break bulk and handling and storing containers, while Zeebrugge is a major port for roll-on/roll-off traffic, container handling and the transshipment of liquid natural gas.

A unified port, said the authorities, will be able to respond more rapidly and more effectively to social and technological developments, such as the energy transition, innovation and digitalization. Specifically, the Port of Antwerp-Bruges aims to be a leading import hub for green hydrogen, as well as playing an “active and pioneering” role in the hydrogen economy.

In addition, in collaboration with industrial and maritime customers, the port will continue efforts to reduce its carbon footprint and transition toward a low-carbon hub. It will carry out a study into the opportunities offered by carbon capture, utilization and storage, and green methanol production from CO2.

The new Antwerp-Bruges will also develop and optimize interconnectivity between the two ports by bundling rail transportation between the sites, making estuary traffic more efficient and prioritizing pipeline connections. Committed investments such as the new sea lock in Zeebrugge and additional container capacity in Antwerp will still go ahead.

Author: Elaine Burridge, Freelance Journalist

The Belgian cities of Antwerp and Bruges are to merge their respective ports....
The Belgian cities of Antwerp and Bruges are to merge their respective ports. The combined ports of Antwerp and Zeebrugge – to be known as the Port of Antwerp-Bruges – will remain Europe’s most important chemical hub and account for more than 15% of European LNG transshipments. (c) Port of Antwerp

Company

Logo:

Antwerp Port Authority

Havenhuis
2030 Antwerp
Belgium

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.